Compare ADUS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | EVO |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.0B |
| IPO Year | 2009 | N/A |
| Metric | ADUS | EVO |
|---|---|---|
| Price | $114.59 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $133.78 | $7.00 |
| AVG Volume (30 Days) | ★ 241.2K | 39.3K |
| Earning Date | 05-04-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.17 | $1.37 |
| Revenue Next Year | $4.70 | $10.05 |
| P/E Ratio | $84.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.95 | $1.95 |
| 52 Week High | $124.44 | $4.42 |
| Indicator | ADUS | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 78.44 | 24.34 |
| Support Level | $106.59 | N/A |
| Resistance Level | $123.09 | $3.36 |
| Average True Range (ATR) | 3.19 | 0.10 |
| MACD | 0.84 | -0.09 |
| Stochastic Oscillator | 85.20 | 4.08 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.